-

BostonGene Highlights Approach to IO Research and Precision Medicine at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene announced today that it will participate in and present at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference on June 22 - 23 in Boston, MA. The event brings together academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest advancements in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy. BostonGene will also exhibit at the conference.

BostonGene session details can be found below:

Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure

  • Friday, June 23 | 9:30 AM ET
  • Speaker: Alexander Bagaev, PhD, Vice President, Product Development, BostonGene

Multiple molecular and cellular factors can influence poor patient responses to immunotherapy and IO clinical trial failure. Although the involvement of these factors is known to impact patient responses, they are often not considered in IO clinical trial enrollment and therapeutic decision-making. This session will address how BostonGene bridges this gap by providing a comprehensive profile or portrait of a patient’s disease for therapy selection and stratification for IO clinical trials.

To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at maria.proia@bostongene.com.

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media:

BostonGene
Erin O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

BostonGene Corporation


Release Versions

Contacts

Media:

BostonGene
Erin O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com

Social Media Profiles
More News From BostonGene Corporation

BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol...

BostonGene Wins Three Gold Stevie® Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie® Awards in the 2026 Stevie® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology. The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective a...
Back to Newsroom